Journal article
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (αIIb/β3) receptor-directed platelet inhibition
Abstract
BACKGROUND: Platelet surface glycoprotein (GP) IIb/IIIa (alphaIIb/beta(3)) receptor inhibition, by preventing fibrinogen binding and platelet aggregation, concomitantly attenuates arterial thrombotic capacity and impairs protective hemostasis, 2 divergent platelet-dependent processes. Because the currently available Food and Drug Administration-approved small molecule GP IIb/IIIa receptor antagonists are considered "competitive" inhibitors and …
Authors
Li YF; Spencer FA; Becker RC
Journal
American Heart Journal, Vol. 142, No. 2, pp. 204–210
Publisher
Elsevier
Publication Date
8 2001
DOI
10.1067/mhj.2001.116962
ISSN
0002-8703